samedan logo

 
 
spacer
home > ict > winter 2019 > animal models to study infectious pathogens
PUBLICATIONS
International Clinical Trials

Animal Models to Study Infectious Pathogens

Until recently, several issues prevented the use of cotton rats (Sigmodon hispidus) as an experimental model on a widespread level. They lacked inbreeding, they were not readily commercially available, and reagents specific to this species had yet to be developed. Additionally, cotton rats are notoriously hard models to work with. Although cotton rats are not normally aggressive, they dislike being handled, can move very rapidly, and jump well. Significant advances have now been made to alleviate these issues. A variety of immunological methods have been established for the cotton rat so that immunological responses after infection or vaccination can be evaluated. Also, a wide variety of chemokine and cytokine genes have been cloned and enzyme-linked immunosorbent assay and other antibody-based systems are readily available. Some strategies can overcome the challenges of working with cotton rats, and their necessity to vaccine development ultimately makes them more than worth the trouble.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Carmen Sweeney PhD is the Scientific Director of in vivo/ex vivo testing services at Charles River’s site, Ballina, Ireland. Carmen has over 20 years’ experience in the industry, having held a number of positions at Charles River, from Study Director, Manager of Methods Development, to her current role. Carmen received her PhD in biological and biomedical sciences and toxicology MSc from the University of Ulster, UK.
spacer
Carmen Sweeney PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement